Yvanne Enever, Founder and CEOPHARMExcel, a full-service, contract research organization (CRO), is well-positioned to make a significant impact in the clinical trial space, with a primary focus on the UK. Combining its extensive knowledge and experience from investigator-led trials, with its strong site connections and commercial acumen, brings a unique value to the commercial trial delivery process.
Driven by its motto, 'Together we make it happen,' PHARMExcel embodies a commitment to collaborative success. It connects with primary care networks and the UK Clinical Research Network (UKCRFN) to deliver a wide range of trial support services from early-phase to post-marketing.
“We’re small enough to care but large enough to deliver,” says Yvanne Enever, founder and CEO of PHARMExcel. “We provide accessible, client-first support for the NHS and the commercial research sector, with the ultimate goal of improving patient health.”
With over 30 years of experience in the field, Enever has established trusted partnerships and strong connections across the UK academic and bioscience sector, enabling PHARMExcel to pass on a wealth of resources and expertise to its sponsors and their clinical research teams. She has cultivated a purpose-driven culture within the company based on four core values—honesty and integrity, transparency, unwavering commitment to quality, and effective teamwork and passion.
PHARMExcel is built on the foundation of a team of competent and experienced operational experts. Positioning itself as an extension of its client, it prioritises round-table discussion with its sponsors proactively contributes to the decision-making process. Its dedication mirrors the passion of clients, driven by the same core values.
Active participation in early conversations with clients enables PHARMExcel to provide valuable insights to enhance the study's design and execution, influencing the best course of action. It also helps clients navigate regulatory hurdles and implement diversity and inclusion strategies in clinical trials to increase access for underrepresented communities. This ensures that clinical trials are more representative and that the outcomes benefit a broader range of patients.
An impactful collaboration with the University of Liverpool in a COVID-19 treatment intervention within a platform trial stands out as a significant success story. The partnership facilitated streamlined discussions regarding study outcomes among various stakeholders, including the sponsor, site representatives, statistical and data management teams, and laboratories.
PHARMExcel exemplifies a commitment to partnership, transparency and responsiveness that sets it apart in the highly competitive CRO landscape
Moving beyond the typical CRO role, PHARMExcel actively participates in initiatives aimed at supporting disease-specific research. Its contributions to organisations like the International Accrediting Organisation for Clinical Research and involvement in disease-specific initiatives like the UK CLIF that focuses on developing new treatments for liver cirrhosis and enhancing patient participation in liver clinical trials in the UK, reflects its dedication to making a meaningful impact in clinical research.
PHARMExcel exemplifies a commitment to partnership, transparency, and innovation that sets it apart in the highly competitive CRO landscape. Possessing a deep understanding of the UK healthcare ecosystem and a passion for making a difference in the industry across the globe, it is a driving force in the world of clinical research, positively influencing the sector and delivering excellence in every trial.


